HealthEquity (HQY) fundamentals: P/E, valuation, undervalued?
HealthEquity · Health Care · ref. ETF XLV · price $93.39
In short — HealthEquity trades at 39.1× earnings (P/E), 17.1× forward, with a net margin of 17.3 % and revenue growth of +7 %. Read: Cheap for the growth (P/E 17 for ~34% growth (PEG 0.5)).
Is HealthEquity stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$93.39+5.8% over range
Aug 28, 25low $73.21 · high $106.79Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 7 analysts
Valuation : Cheap for the growth — P/E 17 for ~34% growth (PEG 0.5)
Valuation
39.1
P/E (price/earnings)
17.1
Forward P/E
1.14
PEG
3.8
Price/book (P/B)
$7.7B
Market cap
2.39
EPS
Profitability & growth
17.3 %
Net margin
+7 %
Revenue growth
+34 %
Earnings growth
$985M
Total debt
HealthEquity income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $862M | $-26M | -3.0 % |
| 2024 | $1000M | $56M | 5.6 % |
| 2025 | $1.2B | $97M | 8.1 % |
| 2026 | $1.3B | $215M | 16.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is HealthEquity's P/E and is the stock undervalued? What's a good P/E?
HealthEquity's P/E is 39.1 (forward 17.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is HealthEquity profitable?
HealthEquity has a net margin of 17.3 % (EPS 2.39). The company is profitable.
Is HQY stock expensive?
Our read: "Cheap for the growth" — P/E 17 for ~34% growth (PEG 0.5). Cross-check with growth and sector.
💬 A question about HealthEquity? The JPI assistant answers using our backtest data.
Keep exploring HealthEquity